Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, has signed an agreement with Orbsen Therapeutics Ltd. and the National University of Ireland, Galway, to utilize Cardium’s FDA-cleared Excellagen® gel as a delivery agent for Orbsen’s proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers.

The research is being conducted by the Regenerative Medicine Institute (REMEDI), at the National University of Ireland Galway’s (NUIG) world-class biomedical research center. The research initiative is funded by REDDSTAR, a European Union Framework 7 (EU FP7) research collaboration focused on the treatment of diabetes and associated complications with a defined MSC therapy. REDDSTAR partners with academic and industry players throughout Europe.

Excellagen is a syringe-based, pharmaceutically formulated an aseptically manufactured, 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly speed up the growth of granulation tissue.

The Excellagen homogenate represents a new product delivery platform that may provide a pathway for a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells, and conditioned cell media. Because it has been cleared by the FDA, Excellagen’s broad labeling includes partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, draining wounds, and trauma wounds such as abrasions, lacerations, second-degree burns, and skin tears.

For more information visit www.cardiumthx.com

Let us hear your thoughts below: